Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.

ABSTRACT:

Background

Primaquine is the only licensed antimalarial for the radical cure of Plasmodium vivax infections. Many countries, however, do not administer primaquine due to fear of hemolysis in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. In other settings, primaquine is given without G6PD testing, putting patients at risk of hemolysis. New rapid diagnostic tests (RDTs) offer the opportunity to screen for G6PD deficiency prior to treatment with primaquine. Here we assessed the cost-effectiveness of using G6PD RDTs on the Thailand-Myanmar border and provide the model as an online tool for use in other settings.

Methods/principal findings

Decision tree models for the management of P. vivax malaria evaluated the costs and disability-adjusted life-years (DALYs) a

SUBMITTER: Devine A 

PROVIDER: S-EPMC5460895 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature